Patient-derived first generation xenografts of non-small cell lung cancers: Promising tools for predicting drug responses for personalized chemotherapy

Clinical Cancer Research

Volumn 16, Issue 5, 2010, Pages 1442-1451

  Dong, Xin ^a   Guan, Jun ^a   English, John C ^b   Flint, Julia ^b   Yee, John ^b   Evans, Kenneth ^b   Murray, Nevin ^a   MacAulay, Calum ^a   Ng, Raymond T ^b   Gout, Peter W ^a   Lam, Wan L ^a   Laskin, Janessa ^a   Ling, Victor ^a   Lam, Stephen ^a   Wang, Yuzhuo ^a,b,c  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c VANCOUVER PROSTATE CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOCETAXEL; GEMCITABINE; NAVELBINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER RESISTANCE; CANCER SURGERY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; DRUG SENSITIVITY; ENGRAFTMENT; HUMAN; HUMAN TISSUE; KIDNEY CAPSULE; LUNG NON SMALL CELL CANCER; METASTASIS; MOUSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; NONOBESE DIABETIC MOUSE; PREDICTION; PRIORITY JOURNAL; SCID MOUSE; TREATMENT OUTCOME; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DEOXYCYTIDINE; HUMANS; INDIVIDUALIZED MEDICINE; LUNG NEOPLASMS; MICE; MICE, INBRED NOD; MICE, SCID; TAXOIDS; VINBLASTINE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77649178137     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-2878     Document Type: Article

References (44)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
2. Spira A, Ettinger DS. Multidisciplinary management of lung cancer. N Engl J Med 2004;350:379-92.
3. Hoffman PC, Mauer AM, Vokes EE. Lung cancer. Lancet 2000;355: 479-85.
4. Pignon JP, Tribodet H, Scagliotti GV, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol 2008;26:3552-9.
5. Anguiano A, Nevins JR, Potti A. Toward the individualization of lung cancer therapy. Cancer 2008;113:1760-7.
6. Bepler G, Begum M, Simon GR. Molecular analysis-based treatment strategies for non-small cell lung cancer. Cancer Control 2008;15:130-9.
7. Rosell R, Cuello M, Cecere F, et al. Treatment of non-small-cell lung cancer and pharmacogenomics: where we are and where we are going. Curr Opin Oncol 2006;18:135-43.
8. Azzoli CG, Park BJ, Pao W, Zakowski M, Kris MG. Molecularly tailored adjuvant chemotherapy for resected non-small cell lung cancer: a time for excitement and equipoise. J Thorac Oncol 2008;3:84-93.
9. Rubio-Viqueira B, Jimeno A, Cusatis G, et al. An in vivo platform for translational drug development in pancreatic cancer. Clin Cancer Res 2006;12:4652-61.
10. Lock RB, Liem N, Farnsworth ML, et al. The nonobese diabetic/severe combined immunodeficient (NOD/SCID) mouse model of childhood acute lymphoblastic leukemia reveals intrinsic differences in biologic characteristics at diagnosis and relapse. Blood 2002;99: 4100-8.
11. Stratton JA, Kucera PR, Rettenmaier MA, et al. Accurate laboratory predictions of the clinical response of patients with advanced ovarian cancer to treatment with cyclophosphamide, doxorubicin, and cisplatin. Gynecol Oncol 1986;25:302-10.
12. Fiebig HH, Maier A, Burger AM. Clonogenic assay with established human tumour xenografts: correlation of in vitro to in vivo activity as a basis for anticancer drug discovery. Eur J Cancer 2004;40: 802-20.
13. Perez-Soler R, Kemp B, Wu QP, et al. Response and determinants of sensitivity to paclitaxel in human non-small cell lung cancer tumors heterotransplanted in nude mice. Clin Cancer Res 2000;6:4932-8.
14. Johnson JR, Hammond WG, Benfield JR, Tesluk H. Successful xenotransplantation of human lung cancer correlates with the metastatic phenotype. Ann Thorac Surg 1995;60:32-6, discussion 6-7.
15. Merk J, Rolff J, Becker M, Leschber G, Fichtner I. Patient-derived xenografts of non-small-cell lung cancer: a pre-clinical model to evaluate adjuvant chemotherapy? Eur J Cardiothorac Surg 2009; 36:454-9.
16. Fichtner I, Rolff J, Soong R, et al. Establishment of patient-derived non-small cell lung cancer xenografts as models for the identification of predictive biomarkers. Clin Cancer Res 2008;14:6456-68.
17. Mattern J, Jager S, Sonka J, Wayss K, Volm M. Growth of human bronchial carcinomas in nude mice. Br J Cancer 1985;51:195-200.
18. Cunha GR. Epithelial-stromal interactions in development of the urogenital tract. Int Rev Cytol 1976;47:137-94.
19. Cunha GR, Lung B, Kato K. Role of the epithelial-stromal interaction during the development and expression of ovary-independent vaginal hyperplasia. Dev Biol 1977;56:52-67.
20. Bogden AE, Griffin W, Reich SD, Costanza ME, Cobb WR. Predictive testing with the subrenal capsule assay. Cancer Treat Rev 1984;11 Suppl A:113-24.
21. Griffin TW, Bogden AE, Reich SD, et al. Initial clinical trials of the subrenal capsule assay as a predictor of tumor response to chemotherapy. Cancer 1983;52:2185-92.
22. Wang Y, Revelo MP, Sudilovsky D, et al. Development and characterization of efficient xenograft models for benign and malignant human prostate tissue. Prostate 2005;64:149-59.
23. Lee CH, Xue H, Sutcliffe M, et al. Establishment of subrenal capsule xenografts of primary human ovarian tumors in SCID mice: potential models. Gynecol Oncol 2005;96:48-55.
24. Cutz JC, Guan J, Bayani J, et al. Establishment in severe combined immunodeficiency mice of subrenal capsule xenografts and transplantable tumor lines from a variety of primary human lung cancers: potential models for studying tumor progression-related changes. Clin Cancer Res 2006;12:4043-54.
25. Winton T, Livingston R, Johnson D, et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 2005;352:2589-97.
26. Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon JP, Vansteenkiste J. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004;350:351-60.
27. Nakagawa K, Tada H, Akashi A, et al. Randomised study of adjuvant chemotherapy for completely resected p-stage I-IIIA non-small cell lung cancer. Br J Cancer 2006;95:817-21.
28. Kraus-Berthier L, Jan M, Guilbaud N, Naze M, Pierre A, Atassi G. Histology and sensitivity to anticancer drugs of two human non-small cell lung carcinomas implanted in the pleural cavity of nude mice. Clin Cancer Res 2000;6:297-304.
29. McWilliams A, MacAulay C, Gazdar AF, Lam S. Innovative molecular and imaging approaches for the detection of lung cancer and its precursor lesions. Oncogene 2002;21:6949-59.
30. Good P. Permutation Tests: A Practical Guide to Resampling Methods for Testing Hypotheses. 2nd ed. : Springer- Verlag NewYork, Inc.; 2000.
31. Sharpless NE, Depinho RA. The mighty mouse: genetically engineered mouse models in cancer drug development. Nat Rev Drug Discov 2006;5:741-54.
32. Voskoglou-Nomikos T, Pater JL, Seymour L. Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models. Clin Cancer Res 2003;9:4227-39.
33. Wang X, Fu X, Hoffman RM. A new patient-like metastatic model of human lung cancer constructed orthotopically with intact tissue via thoracotomy in immunodeficient mice. Int J Cancer 1992;51:992-5.
34. Hoffman RM. Orthotopic metastatic mouse models for anticancer drug discovery and evaluation: a bridge to the clinic. Invest New Drugs 1999;17:343-59.
35. Cuenca RE, Takita H, Bankert R. Orthotopic engraftment of human lung tumours in SCID mice for the study of metastasis. Surg Oncol 1996;5:85-91.
36. Fiebig HH, Schuchhardt C, Henss H, Fiedler L, Lohr GW. Comparison of tumor response in nude mice and in the patients. Behring Inst Mitt 1984:343-52.
37. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346:92-8.
38. Fossella F, Pereira JR, von Pawel J, et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol 2003;21:3016-24.
39. Ramalingam S, Belani C. Systemic chemotherapy for advanced non-small cell lung cancer: recent advances and future directions. Oncologist 2008;13 Suppl 1:5-13.
40. Junker K, Langner K, Klinke F, Bosse U, Thomas M. Grading of tumor regression in non-small cell lung cancer: morphology and prognosis. Chest 2001;120:1584-91.
41. Junker K, Thomas M, Schulmann K, Klinke F, Bosse U, Muller KM. Tumour regression in non-small-cell lung cancer following neoadjuvant therapy. Histological assessment. J Cancer Res Clin Oncol 1997;123:469-77.
42. Junker K. [Therapy-induced morphological changes in lung cancer]. Pathologe 2004;25:475-80.
43. Milano S, Zorzi F, Marini G, et al. Histopathological grading of response to induction chemotherapy in non-small cell lung cancer: a preliminary study. Lung Cancer 1996;15:183-7.
44. Kelly K, Crowley J, Bunn PA, Jr., et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol 2001; 19:3210-8.